Trial Profile

A Phase 2, Open-Label, Safety Lead-In with Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EG-007 (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
Indications Carcinoma; Endometrial cancer
Focus Adverse reactions
Sponsors Evergreen Therapeutics

Most Recent Events

09 Sep 2024 Planned End Date changed from 1 Oct 2025 to 1 Mar 2026.
09 Sep 2024 Planned primary completion date changed from 1 Oct 2025 to 1 Mar 2026.
09 Sep 2024 Planned initiation date changed from 1 Mar 2025 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com